In this video from Boehringer Ingelheim Idiopathic Pulmonary Fibrosis, Professor Vincent Cottin and Professor Luca Richeldi discuss which biomarkers are reliable for the diagnosis of idiopathic pulmonary fibrosis (IPF) and can predict the disease’s progression.
Identifying these biomarkers is essential for speeding up the diagnosis process so that doctors can quickly determine the best treatment path for the patient. The two academics share their prediction that biomarkers will be used more in the future for targeting therapies and in clinical practices for patients with idiopathic pulmonary fibrosis.
Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?